Search clinical trials for: AK104 injection

Total 9905 results

Akeso

Recruiting

A Study of AK109 Combined With AK104 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
Akeso

Recruiting

A Study of AK109 and AK104 in Advanced Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma

Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma

China
Tianjin Medical University Cancer Institute and...

Recruiting

A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Treatment of Biliary Systemic Tumours

Advanced Biliary Systemic Tumours That Has Failed at Least One Prior Systemic Therapy

China
Tianjin Medical University Cancer Institute and...

Recruiting

A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma That Has Failed at Least One Prior Systemic Therapy

China
West China Second University Hospital
The Affiliated Hospital Of Southwest Medical University; Afﬁliated Hospital...

Recruiting

A Study of Concurrent Chemoradiotherapy Followed by Cadonilimab（AK104） for Newly Diagnosed Local Advanced Cervical Cancer

Cervical Cancer

China
Akeso

Recruiting

Open Label Study to Evaluate the Safety and Efficacy of AK101 Injection Subcutaneously in Subjects With Psoriasis

Plaque Psoriasis

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Active, not recruiting

Clinical Trial of the TQB3602 Capsule Combined With AK105 Injection in Patients With Advanced Cancers

Advanced Cancers

China
Akeso

Not yet recruiting

A Phase II Study of AK104 for Recurrent or Metastatic Vulvar Cancer

Vulvar Cancer

China
Akeso

Not yet recruiting

AK104 in Neoadjuvant Treatment of Cervical Cancer

Cervical Cancer

China
Second Affiliated Hospital of Zunyi Medical University
Guizhou Provincial People's Hospital; The First People's Hospital of Zunyi; Guizhou... and other collaborators

Recruiting

Cadonilimab (AK104) With or Without CT as 2rd Line Treatment for ES-SCLC

Immunotherapy | Second-line Treatment

China
Wuhan Union Hospital, China

Recruiting

Cadonilimab (AK104) in the Treatment of Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Akeso

Not yet recruiting

A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection

Hepatocellular Carcinoma

China
Akeso

Active, not recruiting

A Study of AK119 (Anti-CD73) in Combination With AK104 in Subjects With Advanced Solid Tumors

Advanced or Metastatic Solid Tumors

Australia
Akeso

Active, not recruiting

A Trial of AK104 Plus Anlotinib in NSCLC

NSCLC

China
Shenzhen People's Hospital
Sixth Affiliated Hospital, Sun Yat-sen University; The University of Hong Kong-Shenzhen...

Recruiting

Neoadjuvant Cadonilimab Plus Chemotherapy Following Short-Course Radiotherapy in Locally Advanced Rectal Cancer (NeoCaCRT)

Locally Advanced Rectal Carcinoma

China
Chinese PLA General Hospital

Not yet recruiting

A Study of Combination Therapy in NSCLC

Non-small Cell Lung Cancer
Akeso

Not yet recruiting

A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma

Gastric and Gastroesophageal Junction Adenocarcinoma
Tianjin Medical University Cancer Institute and...

Recruiting

Cadonilimab in Combination With Ramucirumab for the Treatment of Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy

Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy

China
Shengjing Hospital

Not yet recruiting

Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast Cancer

Triple Negative Breast Cancer

China
Shanxi Province Cancer Hospital
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Recruiting

A Study of RC48-ADC Combined With Cadonilimab（AK104）in the Treatment of HER2-expression Locally Advanced or Metastatic Urothelial Carcinoma

Urothelial Carcinoma

China
Chongqing University Cancer Hospital
Akeso Pharmaceuticals, Inc.

Recruiting

Study Of Candonilimab Combined With Radiotherapy In The Treatment of Locally Advanced Cervical Cancer

Locally Advanced Cervical Cancer

China
Akesobio Australia Pty Ltd

Recruiting

A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK127 in Combination With AK104 in Advanced and Metastatic Solid Tumours

Advanced or Metastatic Solid Tumours

Australia
M.D. Anderson Cancer Center

Active, not recruiting

Phase II Study of AK104 (Cadonilimab) for Recurrent Small Cell Neuroendocrine Carcinomas of the Cervix

Cervical Cancer | Cervix Cancer | Carcinomas

United States
The Affiliated Nanjing Drum Tower Hospital of Nanjing...
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Study of AK105 With Anlotinib and Radiotherapy Adjuvant Therapy in MGMT Unmethylated Newly Diagnosed Glioblastoma.

MGMT-Unmethylated Glioblastoma

China
Akeso

Completed

A Study to Evaluate the PK Similarity of AK104 in Healthy Chinese Male Subjects

Healthy Male Subjects

China
Peking University

Not yet recruiting

AK104 in Locally Advanced MSI-H/dMMR Gastric Carcinoma and Colorectal Cancer

MSI-H/dMMR Gastric Carcinoma and Colorectal Cancer
Akeso
Akesobio Australia Pty Ltd

Completed

A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical Cancer

Metastatic Cervical Cancer | Recurrent Cervical Cancer

United States, Australia, New Zealand
Akeso
Akeso Pharmaceuticals, Inc.

Terminated

A Study of AK104 in Subjects With Locally Advanced Unresectable or Metastatic MSI-H/dMMR Solid Tumors

MSI-H/dMMR Solid Tumor

China
Akeso
Akeso Pharmaceuticals, Inc.

Completed

A Study of a PD-1/CTLA-4 Bispecific Antibody AK104 in Patients With Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Akeso

Recruiting

Study of AK119 Combined With AK104 in Patients With Advanced Solid Tumors

Solid Tumor, Adult

China
Zhejiang Cancer Hospital

Recruiting

Surufatinib Plus Cadonilimab in Patients With Unresectable or Metastatic Bile Duct Adenocarcinoma

Bile Duct Adenocarcinoma

China
Afyonkarahisar Health Sciences University

Completed

The Efficacy of PRP Injection in the Treatment of Rotator Cuff Syndrome (PRP)

Musculoskeletal Diseases | Shoulder Pain | Rotator Cuff Tendinopathy | Rotator Cuff Syndrome

Turkey
Cancer Institute and Hospital, Chinese Academy...
Shanxi Province Cancer Hospital

Recruiting

A Study of RC48-ADC Combined With AK104 For Perioperative Treatment of Muscle-Invasive Bladder Cancer

Muscle Invasive Bladder Carcinoma

China
RemeGen Co., Ltd.

Recruiting

DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy

Gastric Cancer | Gastroesophageal Junction Adenocarcinoma

China
Akeso

Completed

A Study of AK101 in Subjects With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis

China
Akeso
Akeso Pharmaceuticals, Inc.

Terminated

A Study of PD-1/CTLA-4 Bispecific AK104 in Relapsed or Refractory Peripheral T-cell Lymphoma

Peripheral T-cell Lymphoma

China
Akeso
Akeso Pharmaceuticals, Inc.

Completed

Safety and Efficacy of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Selected Advanced Solid Tumors

Melanoma | Advanced Solid Tumors

China
The First Affiliated Hospital of University of...

Not yet recruiting

AK104 Plus Concurrent Chemoradiation Therapy in Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma
Akeso
Akeso Pharmaceuticals, Inc.

Completed

A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Alone or in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
JIN JING

Not yet recruiting

Assess the Efficacy of Radiotherapy and Sequential Chemotherapy and AK104 Before TME Surgery for Local CRC（AK104-IIT-13） (AK104-IIT-13)

Locally Advanced Rectal Cancer
Harbin Medical University

Not yet recruiting

A Study of Cadonilimab Combined With AK112 as Second-line Therapy in Patients With Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Hunan Cancer Hospital

Not yet recruiting

Cadonilimab in Combination With Anlotinib in the Treatment of Locally Progressive or Metastatic Melanoma With First-Line Therapy Failure

Melanoma
Guangzhou Institute of Respiratory Disease

Not yet recruiting

Cadonilimab in Combination With Chemotherapy for Locally Advaced Esophageal Squamous Cell Carcinoma

Neoadjuvant Therapy | Resectable Esophageal Squamous Cell Carcinoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

A Study of Anlotinib Hydrochloride Capsule Combined With AK105 Injection in Subject With Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma

Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma

China
Akeso

Not yet recruiting

A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Akeso

Recruiting

A Phase Ia/Ib Open Label，Clinical Study Evaluating the Safety, Tolerability and Preliminary Efficacy of AK127 in Combination With AK104 in Patients With Advanced Malignant Tumors

Advanced Malignant Tumors

China
Akeso

Completed

A Phase 3 Study of Efficacy and Safety of AK101 in Subjects With Psoriasis

Psoriasis Vulgaris

China
Akeso
AD Pharmaceuticals Co., Ltd.

Completed

A Study of PCSK9 Inhibitor AK102 in Healthy Subjects

Hypercholesterolaemia

China
Sun Yat-sen University

Not yet recruiting

AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING)

Resectable Hepatocellular Carcinoma
Tianjin Medical University Second Hospital

Recruiting

Cadonilimab Plus Nab-Paclitaxel for Recurrent or Metastatic Muscle Invasive Bladder Cancer

Bladder Cancer

China

3

Subscribe